From: A functional Notch–survivin gene signature in basal breast cancer
Study | n | Median age (years) | Microarray | Tumor size | Lymph nodes (LN) | Treatment | Stage/grade |
---|---|---|---|---|---|---|---|
Chin and colleagues [55] | 118 | 55.3 (SD = 14.3) | Affymetrix | 2.6 cm (SD = 1.3) | 67 LN-positive, 51 LN-negative | 60% tamoxifen, 52% adjuvant chemotherapy, 51% radiation | 26 stage 1, 70 stage 2, 14 stage 3, 5 stage 4; 10 grade 1, 42 grade 2, 61 grade 3; 5 unknown |
Desmedt and colleagues [56] | 198 | 47 (all < 61) | Affymetrix | < 5 cm | Node-negative | T1–T2 | |
Ginestier and colleagues [57] | 55 | Affymetrix | 19 amplified for 20q13, 36 unamplified for 20q13 | Consecutive cases, unilateral localized invasive breast cancer | |||
Hess and colleagues [58] | 133 | Training set, 52 (range 29 to 79); validation set, 50 (range 28 to 73) | Affymetrix | Preoperative weekly paclitaxel and fluorouracil–doxorubicin–cyclophosphamide chemotherapy | Stage I, stage II, stage III | ||
Ivshina and colleagues [59] | 249 (Uppsala cohort) | 62.3 | Affymetrix | 2.9 cm | 35% node-positive | 30.3% endocrine therapy, 10.7% chemotherapy, 1.7% combination therapy, 58.8% no systemic therapy | 68 grade 1, 126 grade 2, 55 grade 3 |
Miller and colleagues [60] | 251 | 62.1 (SD = 13.9) | Affymetrix | 22.4 mm (SD = 12.5) | 84/253 LN metastasis, 160 node-negative, 9 unknown node status | 143 no adjuvant therapy; others with systemic adjuvant therapy, and/or chemotherapy | |
Minn and colleagues [61] | 82 | 55.8 (SD = 13.5) | Affymetrix | 3.68 cm (SD = 1.77 cm) | Average 3.5 (SD = 5.98) axillary LN | Adjuvant chemotherapy and/or hormonal therapy | |
Richardson and colleagues [62] | 39 | Affymetrix | |||||
Saal and colleagues [37] | 105 | 61 (range 26 to 77) | Non-Affymetrix | 27 mm (range 2 to 50 mm) | 65 (62%) LN-positive | Treated uniformly with 2 years of adjuvant tamoxifen | Stage II, primary breast cancer |
Sotiriou and colleagues [63] | 119 (KJ125 dataset) | 45% < 50, 55% > 50 | Affymetrix | 61% < 2 cm, 39% > 2 cm | LN-negative | No adjuvant systemic therapy | 34 grade 1, 46 grade 2, 28 grade 3, 17 not available |
Turashvili and colleagues [32] | 10 | Affymetrix | 3 grade I, 5 grade II, 2 grade III | ||||
van de Vijver and colleagues [64] | 295 | < 52 | Non-Affymetrix | < 5 cm | 151 LN-negative, 144 LN-positive | Modified radical mastectomy or breast-conserving surgery | Stage I or stage II breast cancer |
Wang and colleagues [65] | 286 | 54 (SD = 12) | Affymetrix | LN-negative | No adjuvant treatment | ||
Yu and colleagues [38] | 96 (only 68 with Notch-1 and survivin data) | 55 (SD = 10.9) | Affymetrix | 37.7 mm (SD = 17.9) | 37.5% LN-negative | 2 unknown grade, 5 grade I, 26 grade II, 63 grade III | |
Zhao and colleagues [36] | 59 (35 intraductal carcinoma, 17 intralobular carcinoma; three from each with unknown ER status) | Ductal, 53 (SD = 15.5); lobular, 63.5 (SD = 14.0) | Non-Affymetrix | Ductal, 16 LN-positive, 16 LN-negative, 3 LN unknown; lobular, 7 LN-positive, 7 LN-negative, 4 LN unknown | Ductal, 5 grade I, 19 grade II, 11 grade III; lobular, 17 grade II, 1 grade I |